Veradermics Boosts Capital Through Public Offering and Warrants
TipRanks (Fri, 1-May 5:52 PM ET)
Market Chameleon (Thu, 30-Apr 5:18 AM ET)
Veradermics prices upsized $384M public offering and $30M private placement at $100/share
Seeking Alpha News (Thu, 30-Apr 6:19 AM ET)
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Business Wire (Wed, 29-Apr 10:32 PM ET)
Veradermics Announces Launch of Public Offering
Business Wire (Mon, 27-Apr 5:26 PM ET)
Market Chameleon (Mon, 27-Apr 6:29 AM ET)
Market Chameleon (Mon, 27-Apr 3:51 AM ET)
Business Wire (Mon, 27-Apr 7:00 AM ET)
Business Wire (Sun, 26-Apr 4:00 PM ET)
Business Wire (Mon, 30-Mar 7:30 AM ET)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics trades on the NYSE stock market under the symbol MANE.
As of May 1, 2026, MANE stock price climbed to $101.00 with 862,597 million shares trading.
MANE has a beta of -0.41, meaning it tends to be less sensitive to market movements. MANE has a correlation of 0.01 to the broad based SPY ETF.
MANE has a market cap of $3.54 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that MANE belongs to (by Net Assets): VTI, VXF, SCHA, TOS, LFSC.
MANE support price is $92.02 and resistance is $105.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MANE shares will trade within this expected range on the day.
